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In an era marked by the increasing prevalence of obesity, diabetes, and cardiovascular 
disease, the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) has 
emerged as a transcriptional regulator of metabolism whose activity can be modulated by 
direct binding of small molecules. As the master regulator of fat-cell formation, PPARγ is 
required for the accumulation of adipose tissue and hence contributes to obesity. Yet PPARγ 
ligands are clinically effective antidiabetic drugs, although side effects limit their utility. Can 
PPARγ be targeted with greater benefit and with less risk to patients? The answer depends 
upon the basic biology of PPARγ, and the possibility of selectively modulating the activity 
of this nuclear receptor in a tissue- and target-gene-specific manner.The Obesity Pandemic, the Metabolic Syndrome, 
and PPARγ
An epidemic of obesity is threatening to undermine the 
health of people living in Westernized societies. Obesity 
is a major risk factor for insulin resistance, hyperglycemia, 
abnormal blood lipid profiles, and hypertension, all of which 
contribute to cardiovascular disease leading to stroke and 
myocardial infarction (Eckel et al., 2005). Indeed, cardio-
vascular disease is the major cause of death in the indus-
trialized world, and much of this can be attributed to the 
excess accumulation of adipose tissue. At the crossroads 
of obesity, insulin resistance, and cardiovascular disease is 
the nuclear receptor PPARγ, which is required for adipose 
tissue formation but is also a target of insulin-sensitizing 
drugs for treating diabetes.
Obesity and Insulin Resistance
We will briefly review the pathophysiology of insulin resist-
ance associated with obesity before considering the role of 
PPARγ. In normal physiology, adipose tissue stores energy 
in the form of triglycerides that can be broken down (lipoly-
sis) to release free fatty acids. In obese individuals, adipose 
tissue is characterized by hypertrophic adipocytes that are 
less responsive to insulin and have a higher basal rate of 
fatty-acid release. This leads to increased fatty-acid con-
centrations in the serum and ectopic fat accumulation in 
nonadipose tissues such as liver and muscle. Whole-body 
insulin sensitivity correlates with myocellular lipid content 
and free fatty-acid concentrations, illustrating the deleteri-
ous metabolic consequences of nonadipose lipid storage 
(Boden et al., 1994). Adipose tissue also functions as an 
endocrine organ, secreting many polypeptides that regu-
late metabolism, including insulin sensitizers such as adi-
ponectin and insulin resistance factors such as resistin and 
TNFα (Kershaw and Flier, 2004). Insulin resistance asso-
ciated with obesity is exacerbated by pathophysiological 
changes in the secretion of these factors.PPARγ
PPARγ is a member of the nuclear receptor family that 
includes 48 human transcription factors whose activity is 
regulated by direct binding of steroid and thyroid hormones, 
vitamins, lipid metabolites, and xenobiotics (Chawla et al., 
2001b). Binding of PPARγ to specific DNA sequences 
requires heterodimerization with a second member of the 
nuclear receptor family, retinoic X receptor (RXR). Binding 
of agonist ligands to PPARγ triggers a conformation change 
that attracts transcriptional coactivators, including mem-
bers of the steroid receptor coactivator (SRC) family (McK-
enna and O’Malley, 2002). In the absence of ligand, PPARγ 
has the potential to actively silence genes to which it is 
bound by recruiting transcriptional corepressor complexes 
containing nuclear receptor corepressor (N-CoR) or SMRT 
(silencing mediator of retinoid and thyroid receptors). The 
transcriptional coactivators and corepressors exist in mul-
tiprotein complexes including histone-modifying enzymes, 
such as histone acetyltransferases (notably p300/CBP) 
and histone deacetylases (notably HDAC 3), respectively. 
The activity of these histone-modifying enzymes affects 
gene transcription by altering chromatin structure (McK-
enna and O’Malley, 2002). More detailed information about 
the identification, structure, and function of PPARγ and its 
closest relatives, PPARs α and β (also known as d), can be 
found elsewhere (Desvergne and Wahli, 1999a).
Natural Ligands of PPARγ
A variety of substances have been suggested to be natural 
ligands for PPARγ, including fatty acids and eicosanoids 
(Desvergne and Wahli, 1999b), components of oxidized 
low-density lipoproteins (Nagy et al., 1998), and oxi-
dized alkyl phospholipids including lysophosphatidic acid 
(McIntyre et al., 2003) and nitrolinoleic acid (Schopfer et al., 
2005). The prostaglandin J2 derivative, 15-deoxy-∆12,14-
PGJ2, does not naturally exist at sufficient concentrations 
to activate PPARγ in mammalian cells (Bell-Parikh et al., Cell 123, December 16, 2005 ©2005 Elsevier Inc. 993
2003) and affects cellular pathways other than PPARγ 
(Straus et al., 2000). Moreover, recent studies have pro-
vided functional evidence for an unidentified ligand that is 
produced only transiently during adipocyte differentiation 
(Tzameli et al., 2004). Overall, despite intensive research 
efforts, it remains to be determined whether PPARγ has 
a highly specific natural ligand or whether it operates as 
a physiological lipid sensor activated by the combined 
concentration of weakly activating fatty acids and eicosa-
noids.
PPARγ and Adipocyte Differentiation
Fat cells develop from a fibroblast-like preadipocyte to a 
mature, lipid-enriched adipocyte. The underlying tran-
scriptional regulatory network that controls the maturation 
of adipocytes has been the focus of intense research and 
is reviewed elsewhere (MacDougald and Mandrup, 2002). 
Here we focus on the central role of PPARγ in this process. 
The highest levels of PPARγ are expressed in adipose tis-
sue (Chawla et al., 1994; Tontonoz et al., 1994a). In 1994, 
Spiegelman and colleagues discovered that expression 
and activation of PPARγ was sufficient to induce adipogen-
esis (Tontonoz et al., 1994b). The essential role of PPARγ in 
adipogenesis has been clearly demonstrated in functional 
and genetic knockdown experiments (Barak et al., 1999; 
Rosen et al., 1999).
Two PPARγ isoforms created by differential promoter 
usage and splicing (γ1 and γ2) are found in adipocytes. 
PPARγ2, harboring an additional 30 amino acids at its 
N-terminal end, is expressed specifically in adipocytes, 
whereas PPARγ1 is also relatively abundant in macro-994 Cell 123, December 16, 2005 ©2005 Elsevier Inc.phages, colon epithelia, and endothelium (Marx et al., 
1999; Ricote et al., 1998; Sarraf et al., 1998). Liver and 
muscle express PPARγ1 at much lower levels, although 
tissue-specific gene disruption suggests that PPARγ1 
expression in these tissues may be functionally relevant 
(Hevener et al., 2003; Matsusue et al., 2003; Norris et al., 
2003). Selective in vivo disruption of the PPARγ2 isoform 
has metabolic consequences, with reduced adipose tis-
sue mass observed in some, but not all, studies (Kout-
nikova et al., 2003; Medina-Gomez et al., 2005; Zhang et 
al., 2004). Posttranscriptional modification can also mod-
ulate the activity of both PPARγ isoforms. For example, 
phosphorylation of serine residue 112 in the N terminus 
of PPARγ2 reduces its transcriptional activity (Hu et al., 
1996) and promotes sumoylation on lysine 107, which fur-
ther lowers its ability to act as a transcriptional activator 
(Yamashita et al., 2004).
PPARγ and Adipocyte Metabolism
In addition to its importance in adipogenesis, PPARγ 
plays an important role in regulating lipid metabolism in 
mature adipocytes. Much of what is known about this role 
of PPARγ, and indeed many other aspects of its biology, 
followed the discovery that thiazolidinedione (TZD) anti-
diabetic drugs are high-affinity agonist ligands for PPARγ 
(Lehmann et al., 1995). TZDs appear to coordinately acti-
vate gene expression leading to an increase in net lipid par-
titioning into adipocytes. Target genes directly regulated by 
PPARγ that are involved in this pathway include lipoprotein 
lipase (Schoonjans et al., 1996), fatty-acid transport protein 
(Frohnert et al., 1999), and oxidized LDL receptor 1 (Chui Figure 1. The Many Faces of PPARγ
PPARγ has many activities, leading to complicated and even paradoxical effects on adipocyte biology, insulin action, cardiovascular disease, inflammation, 
renal function, and tumor biology. Shown are some of the various tissues and processes that PPAR affects. The specific gene targets are discussed in 
the text. The ultimate therapeutic potential of small molecule regulators depends upon their ability to selectively modulate PPARγ activity in a gene- and 
tissue-specific manner.
et al., 2005), which all favor adipocyte uptake of circulating 
fatty acids; phosphoenolpyruvate carboxykinase (Tontonoz 
et al., 1995; Tordjman et al., 2003), glycerol kinase (Guan et 
al., 2002), and the glycerol transporter aquaporin 7 (Hibuse 
et al., 2005), which promote recycling rather than export 
of intracellular fatty acids. Together, these pathways lead 
to the net flux of fatty acids from the circulation and other 
tissues into adipocytes (Figure 1). Although increased fat 
storage would be expected to boost the size of adipocytes, 
TZD treatment actually leads to smaller adipocytes (Okuno 
et al., 1998). This is partly due to increased adipocyte dif-
ferentiation, leading to new smaller cells. In addition, TZDs 
induce the coactivator PPARγ-coactivator 1a (PGC-1α), 
which promotes mitochondrial biogenesis (Wilson-Fritch et 
al., 2004), leading to an increase in fatty-acid oxidation that 
further protects against adipocyte hypertrophy.
PPARγ and Insulin Sensitivity
Before they were identified as PPARγ ligands, TZDs were 
found to be effective for treating type 2 diabetes as they 
directly reduced the systemic insulin resistance of periph-
eral tissues (Nolan et al., 1994). Currently, two TZD com-
pounds, rosiglitazone and pioglitazone, are prescribed 
clinically for this purpose. Evidence that PPARγ is the 
insulin-sensitizing target of TZD action includes a strong 
correlation between receptor binding and agonism and the 
biological potency of the glucose-lowering effect in vivo, 
as well as antidiabetic activity of non-TZD-related PPARγ 
agonists (Berger et al., 1999). Genetic studies are also 
consistent with a role of PPARγ in glucose homeostasis. 
Mice with increased PPARγ activity due to a mutation that 
prevents phosphorylation on serine 112 are protected from 
obesity-associated insulin resistance (Rangwala et al., 
2003), whereas mice lacking PPARγ in fat, muscle, or liver 
are predisposed to developing insulin resistance (He et al., 
2003; Hevener et al., 2003; Matsusue et al., 2003; Norris et 
al., 2003). In humans, rare patients with dominant-negative 
mutations in PPARγ are severely insulin resistant (Barroso 
et al., 1999), whereas carriers of a Pro12Ala polymorphism 
in the PPARγ gene display improved glucose homeostasis 
(Deeb et al., 1998).
Despite the broad metabolic relevance of PPARγ in dif-
ferent organs, adipose tissue is likely to be the primary 
target site for the glucose-lowering actions of TZDs. In 
addition to the observation that PPARγ expression is great-
est in adipocytes, mice lacking adipose tissue (Chao et 
al., 2000) or adipose PPARγ (He et al., 2003) are refrac-
tory to the insulin-sensitizing effects of TZDs. Also, TZDs 
retain their glucose-lowering capacities in PPARγ-specific 
knockout models of the liver and muscle, the two main glu-
cose-disposing organs (Matsusue et al., 2003; Norris et 
al., 2003), although muscle PPARγ appears to contribute 
in one mouse model (Hevener et al., 2003).
The mechanism by which TZD activation of adipocyte 
PPARγ leads to insulin sensitivity is of much interest. 
Although TZDs directly modulate adipocyte glucose 
uptake, glucose disposal into adipose tissue contrib-
utes only modestly to the hypoglycemic effects of insulin. Therefore, it is apparent that TZD action must also alter 
communication between adipose tissue and the muscle 
and liver, the main insulin-sensitive organs. Remarkably, 
TZDs induce expression of the insulin-sensitizing factor, 
adiponectin, and simultaneously reduce adipocyte expres-
sion of several insulin resistance-promoting polypeptides. 
This causes the lowering of serum fatty-acid levels by pro-
moting flux into adipose tissue as described above and 
reducing adipocyte production of cortisol (reviewed in 
Rangwala and Lazar, 2004) (Figure 1). All of these effects 
promote insulin sensitivity.
PPARγ and Body Weight
The success of TZDs as a therapy for type 2 diabetes is 
paradoxical, as they target PPARγ, an adipogenic tran-
scription factor, yet adiposity is a major risk factor for type 
2 diabetes. The ability of TZDs to alter the secretion of fac-
tors derived from adipocytes and reduce free fatty-acid 
levels plausibly explains their benefit. Yet one unwanted 
side effect of TZD treatment is modest weight gain. Part 
of the weight gain is explained by increased adipogenesis 
as well as the net flux of fatty acids into adipose tissue, 
which contributes to the antidiabetic effect. However, TZDs 
also increase weight via fluid retention and expansion of 
the extracellular volume, which is especially a problem for 
patients with preexisting congestive heart failure (Mudaliar 
et al., 2003). Although the mechanism of TZD-depend-
ent fluid retention is not completely understood, recent 
advances have focused attention on PPARγ activation 
in the collecting duct of the kidney (Figure 1), as specific 
loss of PPARγ in this region prevents fluid retention and 
weight gain induced by TZD (Guan et al., 2005b; Zhang 
et al., 2005). The molecular mechanism involves PPARγ-
dependent induction of the Na transporter ENaC (Guan et 
al., 2005b). Interestingly, amiloride, a clinically used diuretic 
that directly inhibits ENaC, was able to block TZD-depend-
ent weight gain in mice, presenting a potentially specific 
tool for clinical use (Guan et al., 2005b).
PPARγ in Macrophage Biology and Atherosclerosis
PPARγ is expressed in blood cells and induced during 
macrophage differentiation (Ricote et al., 1998). As affector 
cells of the innate immune system, macrophages combine 
pathogen-clearing capacities with immune modulatory 
function. Attenuated lipid derivates like oxidized LDL are 
part of the pattern recognition code that triggers phago-
cytosis (Li and Glass, 2002). The absence of feedback 
mechanisms limiting lipid uptake can result in massive 
intracellular cholesterol accumulation in a lipid-saturated 
environment, which creates the foamy appearance of 
macrophages seen in atherosclerotic lesions. This proc-
ess involves PPARγ, as well as many of its target genes, 
with functional implications for lipid utilization (Wellen and 
Hotamisligil, 2003).
In macrophages, PPARγ-dependent lipid uptake and 
storage were initially suggested to increase foam-cell for-
mation and, potentially, atherosclerosis (Nagy et al., 1998). 
Despite these concerns, however, TZD treatment proved Cell 123, December 16, 2005 ©2005 Elsevier Inc. 995
vasoprotective and reduced atherosclerosis in mouse 
models (Li et al., 2000a) (Figure 1). Furthermore, transplan-
tation of PPARγ null bone marrow to mice lacking LDL that 
are therefore atherosclerosis prone further demonstrated a 
direct athero-protective role of PPARγ in the macrophage 
(Chawla et al., 2001a). Retrospective human studies have 
also suggested an athero-protective effect of TZDs (Min-
amikawa et al., 1998), and a recent, prospective trial dem-
onstrated that TZD therapy protected patients with type 2 
diabetes, albeit modestly, from cardiovascular events (Dor-
mandy et al., 2005). The solution to the paradox of PPARγ 
increasing lipid uptake in macrophages without increasing 
atherosclerotic risk has focused on the activation of lipid 
efflux pathways, such as reverse cholesterol transport, that 
prevent atherosclerotic lipid accumulation (Chawla et al., 
2001a; Chinetti et al., 2001).
PPARγ and Inflammation
An alternative and primarily lipid-independent explanation 
for the antiatherosclerotic effects of TZDs are the anti-
inflammatory capacities of PPARγ (Li et al., 2004). TZDs 
inhibit the expression of various inflammatory proteins like 
iNOS, TNFα, and MMP9 in macrophages (Li et al., 2000b) 
and are beneficial in disorders such as inflammatory bowel 
disease (Su et al., 1999). Several anti-inflammatory mech-
anisms have been suggested, including inhibition of NF-
κB, AP1, and STAT transcription factors by PPARγ (Welch 
et al., 2003). Although nuclear receptors repress target 
genes in the absence of ligand by recruiting corepressors, 
the molecular mechanism for transcriptional repression 
by nuclear receptors in response to the binding of ligands 
remains poorly understood. One possibility involves the 
reciprocal inhibition of differential transcription systems 
through limited availability of shared cofactors, sometimes 
referred to as squelching. A recent report by Glass and 
colleagues suggests an alternative mechanism, wherein a 
functionally distinct pool of PPARγ is susceptible to ligand-
dependent sumoylation at lysine 365, leading to recruit-
ment to and stabilization of N-CoR complexes at the pro-
moters of proinflammatory genes thereby repressing them 
(Pascual et al., 2005). It remains to be determined whether 
TZDs downregulate adipocytokine gene expression by the 
same mechanisms.
PPARγ and Cancer
In addition to its metabolic and anti-inflammatory proper-
ties, PPARγ has been implicated both as a tumor suppres-
sor and tumor promoter (Figure 1). It is expressed in many 
cancers, including colon, breast, and prostate, and PPARγ 
ligands are generally antiproliferative in these settings 
(Grommes et al., 2004). However, although PPARγ has 
characteristics of a colon cancer tumor suppressor (Sarraf 
et al., 1999), colon tumors with mutations in the APC gene 
appear to be an exception as TZDs promote growth in 
these tumors (Lefebvre et al., 1998; Saez et al., 1998). Fur-
thermore, although the data are not in the peer-reviewed 
literature, reports of hemangiosarcoma and other tumors 
in rodents treated with PPARγ ligands has led the US Food 996 Cell 123, December 16, 2005 ©2005 Elsevier Inc.and Drug Administration to require two-year pre-clinical 
cancer surveillance studies before approving any new drug 
whose target is PPARγ (J. El-Hage, Preclinical and Clinical 
Safety Assessments for PPAR Agonists, http://www.fda.
gov/cder/present/DIA2004/elhage_files/frame.htm).
Selective PPARγ Modulation
The unique ability of PPARγ ligands to improve insulin 
resistance is clearly tempered by side effects that limit their 
clinical use. In the case of another nuclear receptor, estro-
gen receptor α (ERα), similar considerations have led to 
the development of selective estrogen receptor modulators 
(SERMs), which have improved therapeutic index in breast 
cancer and osteoporosis because they regulate ERα activ-
ity in a tissue- and gene-selective manner. Examination 
of the properties of PPARγ in adipocytes suggests that it 
may be possible to selectively modulate PPARγ activity in 
an analogous fashion. For example, PPARγ is required for 
the expression of the adipocyte-specific fatty-acid bind-
ing protein aP2 (Tontonoz et al., 1994a). In mature adi-
pocytes, even in the absence of a pharmaceutical ligand, 
PPARγ binds to the aP2 promoter along with coactivator 
proteins (Chui et al., 2005; Guan et al., 2005a). Whether 
this is due to constitutive activity of PPARγ or to the pres-
ence of an endogenous ligand is not clear. Yet, in the same 
cells, other PPARγ target genes such as glycerol kinase 
and OLR-1 require an exogenous ligand for activation (Chui 
et al., 2005; Guan et al., 2005a). In the absence of TZD or 
other potent synthetic ligand, PPARγ recruits corepressors 
to these genes. This observation may be related to the sur-
prisingly improved insulin sensitivity of PPARγ heterozygote 
null mice (Kubota et al., 1999; Miles et al., 2000), whose 
PPARγ target genes in adipose tissue might be dere-
pressed by the reduced content of PPARγ in the absence 
of exogenous ligand.
Differential modulation of PPARγ activity is also apparent 
from the effects of a form of this protein rendered consti-
tutively active by fusion to the powerful VP16 transactiva-
tion domain. This VP16-PPARγ is sufficient to turn on the 
adipogenic gene program yet differs from PPARγ bound 
to a ligand because, unlike TZDs, it does not transrepress 
genes such as the insulin resistance factor resistin (Li and 
Lazar, 2002). PPARγ activity can also be selectively modu-
lated at the level of coactivator availability. For example, 
the SRC-family coactivator TIF2 (or SRC-2) preferentially 
regulates fat storage in white adipose tissue, whereas in 
brown adipose tissue the related SRC-1 works in concert 
with PGC-1α to facilitate induction of uncoupling protein 1 
and the stimulation of oxidative metabolism (Picard et al., 
2002). Of note, tissue-selective cofactor recruitment is also 
a hallmark of SERMs (Shang and Brown, 2002).
Several PPARγ ligands that function as partial agonists 
(maximal efficacy is less than that of full agonists even at 
saturating concentrations) appear to be effective insulin 
sensitizers with less effect on adipocyte differentiation. One 
such compound is MCC-555, whose ability to stimulate 
PPARγ activity is highly context specific (Reginato et al., 
1998). In addition to only modestly activating target genes, 
some partial agonists, such as FMOC-L-leucine (Rocchi et 
al., 2001), may have gene-specific effects related to dif-
ferential coactivator recruitment. Thus, partial agonists can 
selectively modulate PPARγ activity by creating interfaces 
that affect coactivator binding qualitatively as well as quan-
titatively. In addition, as the corepressors and coactivators 
interface with overlapping surfaces on the receptor (Hu 
and Lazar, 1999; Xu et al., 2002), partial agonism may also 
result from ligand inducing an intermediate conformation 
that is recognized by both classes of cofactors. Moreover, 
partial agonists may have full transrepression activity (Pas-
cual et al., 2005), thereby providing a distinct mechanism 
of selective modulation of PPARγ activity. Partial activation 
can also be achieved by preventing the phosphorylation of 
PPARγ, which increases insulin sensitivity without weight 
gain (Rangwala et al., 2003).
Conclusion and Future Prospects
PPARγ indeed has many faces. It is the master regulator 
of adipocyte differentiation yet promotes insulin sensitiv-
ity. It enhances macrophage lipid uptake as well as lipid 
export and has anti-inflammatory effects. It is generally 
antiproliferative yet has been suggested to exacerbate 
the growth of certain tumors. Hence, targeting this recep-
tor for therapeutic purposes while minimizing side effects 
represents a great challenge. Nevertheless, it is clear that 
selective PPARγ modulation of desired gene sets can be 
achieved by targeting corepressor interactions, separating 
transactivation from transrepression, and favoring specific 
subsets of coactivators. The specific modulation of these 
properties of PPARγ should allow optimization of tissue 
and target gene specificity, thereby enhancing therapeutic 
efficacy, particularly for metabolic diseases, while reducing 
undesired side effects that are limitations for the PPARγ 
compounds currently in the clinic.
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